Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462616 | 1.00 | TYR (0.49) | TYRSERPINE1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6455210 | 0.88 | TYR (0.51) | TYRSERPINE1KMT2ACYP2D6L3MBTL1 | |
| SCHEMBL6455207 | 0.88 | TYR (0.51) | TYRSERPINE1KMT2ACYP2D6L3MBTL1 | |
| SCHEMBL6456297 | 0.84 | TYR (0.52) | TYRSERPINE1KMT2ACYP2D6SCN1A | |
| SCHEMBL6456292 | 0.84 | TYR (0.52) | TYRSERPINE1KMT2ACYP2D6SCN1A | |
| SCHEMBL6450371 | 0.83 | TYR (0.49) | TYRSERPINE1KMT2ACYP2D6SCN1A | |
| SCHEMBL6450374 | 0.83 | TYR (0.49) | TYRSERPINE1KMT2ACYP2D6SCN1A | |
| SCHEMBL6455408 | 0.82 | SCN1A (0.56) | TYRSERPINE1KMT2ACYP2D6SCN1A | |
| SCHEMBL6455403 | 0.82 | SCN1A (0.56) | TYRSERPINE1KMT2ACYP2D6SCN1A | |
| SCHEMBL6455338 | 0.81 | TYR (0.49) | TYRSERPINE1KMT2ACYP2D6SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | claimed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | claimed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | claimed |
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050143594-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART E (GB) | 2005-06-30 | — | — | US | disclosed |
| US-6861564-B2 | Process for preparing resorcinol derivatives | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART EDWARD (GB) | 2003-05-08 | — | — | US | disclosed |
| US-6504037-B2 | Reacting a cyclohexanedione or chromene-one derivative with 1,8-diazabicyclo(5.4.0)undec-7ene | WARNER-LAMBERT COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143594-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | TYR 572/4885SERPINE1 4280/4885SLC6A3 597/4885 |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | TYR 572/4885SERPINE1 4280/4885SLC6A3 597/4885 |
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | TYR 9/4885SERPINE1 2093/4885SLC6A3 1479/4885 |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | TYR 572/4885SERPINE1 4280/4885SLC6A3 597/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | TYR 9/4885SERPINE1 2093/4885SLC6A3 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.